Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy

Journal of Thoracic Oncology

Volumn 4, Issue 3, 2009, Pages 326-332

  Koch, Andrea ^a,b   Fohlin, Helena ^a   Sörenson, Sverre ^a,b,c  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c Department of Clinical Microbiology   (Sweden)

Author keywords

C reactive protein; NSCLC; Palliative treatment; Prognostic factors; Smoking

Indexed keywords

C REACTIVE PROTEIN; CARBOPLATIN; GEMCITABINE; NAVELBINE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SMOKING; SMOKING HABIT; SURVIVAL RATE; SURVIVAL TIME; BLOOD; CANCER STAGING; COMPARATIVE STUDY; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PALLIATIVE THERAPY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SMOKING; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 67049168039     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31819578c8     Document Type: Article

References (26)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-592. (Pubitemid 46359643)
2. Lung cancer in Sweden 2002-2006. The Swedish Lung Cancer Registry. Available at: http://www.roc.se. Accessed July 1, 2008.
3. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-1057.
4. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860-867. (Pubitemid 36019639)
5. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002;4:250-255.
6. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-1812.
7. Tillett WS, Francis T. Serological reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. J Exp Med 1930;52:561-571.
8. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 2004;90:1704-1706.
9. Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002;87:264-267. (Pubitemid 34888575)
10. Pelliniemi TT, Irjala K, Mattila K, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 1995;85:765-771.
11. Tartour E, Dorval T, Mosseri V, et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994;69:911-913. (Pubitemid 24140673)
12. Jabs WJ, Busse M, Kruger S, et al. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int 2005;68:2103-2110. (Pubitemid 43117784)
13. Graff J. C-reactive protein as a prognostic marker for men with androgen- independent prostate cancer (AIPC): results from the ASCENT trial. ASCO Meeting Abstr 2007;26:abstract 5074.
14. Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998;176:335-338. (Pubitemid 28514444)
15. Huang A, Tsavellas G. Acute-phase protein, survival and tumour recurrence in patients with colorectal cancer. Br J Surg 2001;88:1128.
16. Hara M, Matsuzaki Y, Shimuzu T, et al. Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res 2007;27: 3001-3004. (Pubitemid 47228036)
17. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003;89:1028-1030. (Pubitemid 37239206)
18. Scott HR, McMillan DC, Brown DJ, Forrest LM, McArdle CS, Milroy R. A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. Lung Cancer 2003;40:295-299. (Pubitemid 36627709)
19. Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest 2004;126:347-351. (Pubitemid 39093415)
20. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 2006;106:2428-2436. (Pubitemid 43787667)
21. Itaya T, Yamaoto N, Ando M, et al. Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. Cancer Sci 2007;98: 226-230. (Pubitemid 44941875)
22. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
23. Janjigian YY, McDonnell K, Kris MG, et al. Pack years of cigarette smoking as a predictor of survival in 2,013 patients with stage IIIb/IV non-small cell lung cancer (NSCLC). ASCO Meeting Abstr, 2008: abstract 8005.
24. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset publication No 48. Geneva: WHO; 1979.
25. Duarte RL, Luiz RR, Paschoal ME. The cigarette burden (measured by the number of pack-years smoked) negatively impacts the response rate to platinum-based chemotherapy in lung cancer patients. Lung Cancer 2008;61:244-254.
26. Dasgupta P, Kinkade R, Joshi B, et al. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A 2006;103:6332-6337.